On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes

被引:1
|
作者
Eren, Ayse [1 ]
Moon, David [2 ]
Curran, Timothy [3 ]
Luciani, Carla [1 ]
机构
[1] Vertex Pharmaceut, Pharmaceut Sci Engn & Mat Sci, 50 Northern Ave, Boston, MA 02210 USA
[2] Vertex Pharmaceut, Pharmaceut Sci Analyt Dev, 50 Northern Ave, Boston, MA 02210 USA
[3] Vertex Pharmaceut, Pharmaceut Sci Proc Chem, 50 Northern Ave, Boston, MA 02210 USA
关键词
N-NITROSAMINES; KINETICS; DECOMPOSITION;
D O I
10.1016/j.coche.2024.101030
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nitrosamine risk assessments are useful to identify processes and/or materials that exhibit legitimate safety concerns to evaluate appropriate actions and controls. Fundamental understanding of nitrosamine toxicity, formation pathways, fate, and purge aid risk quantification. In this work, available digital tools to aid nitrosamine risk assessments are reviewed. From structure-activity relationships through kinetic models to purge factors, these tools can shed light on the various aspects of a nitrosamine risk assessment. While tremendous progress has been made over the last few years, industry, academia, and government still need to focus on supporting science-based decisions and the integration of diverse tools to provide a holistic view of the nitrosamine risk.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities
    Bharate, Sonali S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (06) : 2923 - 2936
  • [22] Particle engineering at the drug substance, drug product interface: a comprehensive platform approach to enabling continuous drug substance to drug product processing with differentiated material properties
    Schenck, Luke
    Koynov, Athanas
    Cote, Aaron
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2019, 45 (04) : 521 - 531
  • [23] Lead-time and risk reduction assessment of a sterile drug product manufacturing line using simulation
    Spindler, Jannik
    Kec, Thomas
    Ley, Thomas
    COMPUTERS & CHEMICAL ENGINEERING, 2021, 152
  • [24] Models for Designing Hydrogen Peroxide Decontamination Processes in Sterile Drug Product Manufacturing
    Yabuta, Keisho
    Futamura, Haruka
    Kawasaki, Koji
    Hirao, Masahiko
    Sugiyama, Hirokazu
    28TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING, 2018, 43 : 1613 - 1618
  • [25] Optimizing manufacturing processes with digital factory tools
    Linner, S
    Geyer, M
    Wunsch, A
    VIRTUAL PRODUCT DESIGN IN AUTOMOTIVE ENGINEERING, 1999, 1489 : 187 - 198
  • [26] Small-Scale Continuous Drug Product Manufacturing using Dropwise Additive Manufacturing and Three Phase Settling for Integration with Upstream Drug Substance Production
    Sundarkumar, Varun
    Nagy, Zoltan K.
    V. Reklaitis, Gintaras
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 111 (08) : 2330 - 2340
  • [27] Application of high throughput technologies to drug substance and drug product development
    Gardner, CR
    Almarsson, O
    Chen, HM
    Morissette, S
    Peterson, M
    Zhang, Z
    Wang, S
    Lemmo, A
    Gonzalez-Zugasti, J
    Monagle, J
    Marchionna, J
    Ellis, S
    McNulty, C
    Johnson, A
    Levinson, D
    Cima, M
    COMPUTERS & CHEMICAL ENGINEERING, 2004, 28 (6-7) : 943 - 953
  • [28] Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities
    J. Bercu
    S. C. Berlam
    J. Berridge
    B. Cherney
    D. Cowley
    H. W. Laughton
    D. McLoughlin
    M. McMahon
    C. M. V. Moore
    C. Murti
    J. O’Neill
    R. Parsons
    D. Y. Peng
    R. W. Quan
    A. K. Subashi
    A. Teasdale
    S. M. Tyler
    T. J. Watson
    Journal of Pharmaceutical Innovation, 2019, 14 : 76 - 89
  • [29] Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities
    Bercu, J.
    Berlam, S. C.
    Berridge, J.
    Cherney, B.
    Cowley, D.
    Laughton, H. W.
    McLoughlin, D.
    McMahon, M.
    Moore, C. M. V.
    Murti, C.
    O'Neill, J.
    Parsons, R.
    Peng, D. Y.
    Quan, R. W.
    Subashi, A. K.
    Teasdale, A.
    Tyler, S. M.
    Watson, T. J.
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2019, 14 (01) : 76 - 89
  • [30] Manufacturing of [14C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil
    Roberts, Scott W.
    Bezemer, Jeroen M.
    Kennedy, Michael T.
    Correll, Tiffany L.
    Subramanian, Raju
    Walker, Shawn D.
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (05) : 609 - 615